Official Title
Maintenance Versus Reduction of Immunosuppression for Renal Transplant Patients Hospitalized With COVID-19 Disease
Brief Summary

This will be a randomized trial of maintenance versus reduction in immunosuppression in adult patients (age >18 years old) with functioning renal transplants admitted to hospital with confirmed COVID-19 disease.

Detailed Description

The optimal management of immunosuppression in renal transplant patients with COVID-19
disease is unclear. On one hand, many centers advocate reduction of immunosuppression in
infected patients, with the rationale that such an approach will unleash the anti-viral
T-cell response. However, on the other hand, some centers advocate there may be rationale to
maintain baseline immunosuppression in order to mitigate against development of an
uncontrolled over-activation of the immune response. The investigators propose to address
this knowledge gap by performing a randomized clinical trial that will test formal
comparisons of maintenance versus reduction in immunosuppression.

Withdrawn
COVID
Kidney Transplant; Complications
Immunosuppression

Other: Maintenance or reduction of immunosuppression

Maintenance versus reduction of immunosuppression

Eligibility Criteria

Inclusion Criteria:

- Adults ≥18 years

- COVID positive by RT-PCR or serology

- ≥ 6 months post-transplant

- use of anti-metabolite (mycophenolate or azathioprine) and calcineurin inhibitor
(cyclosporin or tacrolimus)

- informed consent; first admission during study period

- participation within 72 hours of hospitalization

Exclusion Criteria:

- ICU care or need for invasive ventilation or use of pressors at
screening/randomization

- COVID-19 disease severity score more than 5 at screening/randomization

- Known donor specific antibody

- eGFR <20ml/min/1.73m2

- hematocrit <24%

- biopsy proven and treated rejection within last 3 months

- institutionalized individuals (prisoners)

- pregnancy

- participation in another clinical study with an investigational medicinal product
within 30 days or within 5 half-lives of such, whichever is longer, prior to
randomization and during the study

- any other conditions, which, in the opinion of the investigator would make the subject
unsuitable.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A

Jamil Azzi, MD, PhD, Principal Investigator
Birgham and Women's Hospital

Brigham and Women's Hospital
NCT Number